Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
|Market Cap||Shares Float||Float Held by Institutions %||Shares Outstanding||Shares Authorized||Institutional Own %|
|13.44 M||4.08 M||16.82%||5.49 M||100.00 M||11.90%|
|Date of Short Interest by FINRA||Shares Sold Short||Short Float %||Insider Own %||Number Institutions Holding Shares||MVPHS|
|31-Aug-2023||0.01 M||0.31%||29.21%||16||$13.50 M|
|Financial Doc Link||Date of Doc||Cash Equivalents||Marketable Securities||Burn Rate Operating Activities (monthly)||Operating Expenses (monthly)||Estimated Months Left of Cash|
|10-Q||10-Nov-2022||$34.50 M||$8.03 M||$1.65 M||$1.50 M||15.91|
|Current Assets||Current Liabilities||Working Capital||Total Assets||Total Liabilities||Total Revenues (12 mo)|
|$56.09 M||$1.90 M||$54.19 M||$84.45 M||$2.60 M||Unavailable|
Dilutive convertible shares can impact a stock's price by increasing the number of outstanding shares, potentially reducing the value of existing shares and decreasing the stock price.
Stock Warrants can increase share count when exercised. This dilutions affects earnings per share and potentially reduces stock value and impacting investments.
Shelf Registrations can impact a stock's price by increasing the supply of shares available for sale, potentially lowering demand and decreasing stock price, leading to decreased returns on investors.
Registration Statements, which provide information on a company's financials and business plans before a public offering, can impact trading by affecting investor perception and demand for the stock, potentially leading to price changes.
Company current reports can impact investments by providing important information on material events and changes at the company, affecting the stock price and potential for gains or losses.